CBD Life Sciences Inc. (CBDL) Announces Groundbreaking 100MG Full Spectrum CBD Gummy Geared Toward Mental Health & Focus
CBD Life Sciences Inc. (OTC:CBDL) has launched a groundbreaking 100MG Full Spectrum CBD Gummy targeting mental health and focus. The product, available in Crisp Green Apple and Wild Blueberry flavors, is positioned as a natural alternative for mental clarity and emotional well-being.
The launch comes as the global CBD market is projected to exceed $60 billion by 2030, with the mental wellness industry surpassing $500 billion. The company's CEO, Lisa Nelson, emphasizes this product's role in addressing mental health challenges without pharmaceutical side effects.
Key features include:
- Lab-tested formulation with verified Certificates of Analysis (COAs)
- Full-spectrum cannabinoids for enhanced effectiveness
- Target audience includes entrepreneurs, creatives, students, and professionals
The company is currently in preliminary discussions with wellness clinics and mental health centers for potential integration into patient routines, though no formal agreements have been established.
CBD Life Sciences Inc. (OTC:CBDL) ha lanciato un innovativo Gummy al CBD Full Spectrum da 100MG dedicato alla salute mentale e alla concentrazione. Il prodotto, disponibile nei gusti Mela Verde Croccante e Mirtillo Selvatico, si propone come un'alternativa naturale per la chiarezza mentale e il benessere emotivo.
Il lancio avviene in un momento in cui il mercato globale del CBD è previsto superare i 60 miliardi di dollari entro il 2030, con l'industria del benessere mentale che supera i 500 miliardi di dollari. La CEO dell'azienda, Lisa Nelson, sottolinea il ruolo di questo prodotto nell'affrontare le sfide della salute mentale senza gli effetti collaterali dei farmaci.
Caratteristiche principali includono:
- Formulazione testata in laboratorio con Certificati di Analisi (COA) verificati
- Cannabinoidi a spettro completo per una maggiore efficacia
- Target comprendente imprenditori, creativi, studenti e professionisti
L'azienda è attualmente in trattative preliminari con cliniche del benessere e centri di salute mentale per una possibile integrazione nelle routine dei pazienti, anche se non sono stati ancora stipulati accordi formali.
CBD Life Sciences Inc. (OTC:CBDL) ha lanzado una innovadora Gominola de CBD de Espectro Completo de 100MG enfocada en la salud mental y la concentración. El producto, disponible en sabores Manzana Verde Crujiente y Arándano Silvestre, se presenta como una alternativa natural para la claridad mental y el bienestar emocional.
El lanzamiento se produce en un momento en que se proyecta que el mercado global del CBD superará los 60 mil millones de dólares para 2030, con la industria del bienestar mental superando los 500 mil millones de dólares. La CEO de la compañía, Lisa Nelson, destaca el papel de este producto para abordar los desafíos de la salud mental sin los efectos secundarios de los medicamentos.
Características clave incluyen:
- Formulación probada en laboratorio con Certificados de Análisis (COA) verificados
- Cannabinoides de espectro completo para una mayor efectividad
- Audiencia objetivo que incluye emprendedores, creativos, estudiantes y profesionales
La empresa está en conversaciones preliminares con clínicas de bienestar y centros de salud mental para una posible integración en las rutinas de los pacientes, aunque aún no se han establecido acuerdos formales.
CBD Life Sciences Inc. (OTC:CBDL)는 정신 건강과 집중력 향상을 목표로 하는 획기적인 100MG 풀 스펙트럼 CBD 구미를 출시했습니다. 이 제품은 크리스프 그린 애플과 와일드 블루베리 맛으로 제공되며, 정신적 명료성과 정서적 안녕을 위한 자연스러운 대안으로 자리매김하고 있습니다.
이번 출시는 글로벌 CBD 시장이 2030년까지 600억 달러를 초과할 것으로 예상되는 가운데, 정신 건강 산업은 5000억 달러를 넘을 것이라는 전망과 맞물려 있습니다. 회사 CEO인 리사 넬슨은 이 제품이 약물 부작용 없이 정신 건강 문제를 해결하는 데 중요한 역할을 한다고 강조했습니다.
주요 특징은 다음과 같습니다:
- 검증된 분석 증명서(COA)를 갖춘 실험실 테스트 공식
- 효과 증진을 위한 풀 스펙트럼 칸나비노이드
- 대상 고객은 기업가, 창작자, 학생 및 전문가 포함
회사는 현재 웰니스 클리닉 및 정신 건강 센터와 환자 루틴에 통합할 가능성에 대해 초기 논의를 진행 중이나, 아직 공식적인 계약은 체결되지 않았습니다.
CBD Life Sciences Inc. (OTC:CBDL) a lancé un bonbon gélifié CBD Full Spectrum 100MG révolutionnaire ciblant la santé mentale et la concentration. Le produit, disponible aux saveurs Pomme Verte Croquante et Myrtille Sauvage, se positionne comme une alternative naturelle pour la clarté mentale et le bien-être émotionnel.
Ce lancement intervient alors que le marché mondial du CBD devrait dépasser 60 milliards de dollars d'ici 2030, avec l'industrie du bien-être mental dépassant 500 milliards de dollars. La PDG de l'entreprise, Lisa Nelson, souligne le rôle de ce produit dans la prise en charge des défis de la santé mentale sans les effets secondaires des médicaments.
Les caractéristiques clés comprennent :
- Formulation testée en laboratoire avec des certificats d'analyse (COA) vérifiés
- Cannabinoïdes à spectre complet pour une efficacité renforcée
- Public cible incluant entrepreneurs, créatifs, étudiants et professionnels
L'entreprise est actuellement en discussions préliminaires avec des cliniques de bien-être et des centres de santé mentale pour une éventuelle intégration dans les routines des patients, bien qu'aucun accord formel n'ait encore été conclu.
CBD Life Sciences Inc. (OTC:CBDL) hat ein bahnbrechendes 100MG Full Spectrum CBD Gummy auf den Markt gebracht, das auf mentale Gesundheit und Konzentration abzielt. Das Produkt ist in den Geschmacksrichtungen Knackiger Grüner Apfel und Wilder Blaubeere erhältlich und wird als natürliche Alternative für geistige Klarheit und emotionales Wohlbefinden positioniert.
Der Launch erfolgt zu einem Zeitpunkt, an dem der globale CBD-Markt voraussichtlich bis 2030 über 60 Milliarden US-Dollar erreichen wird, während die Mental-Wellness-Branche über 500 Milliarden US-Dollar übersteigt. Die Geschäftsführerin des Unternehmens, Lisa Nelson, betont die Rolle dieses Produkts bei der Bewältigung von psychischen Herausforderungen ohne pharmazeutische Nebenwirkungen.
Wesentliche Merkmale umfassen:
- Laborgetestete Formulierung mit verifizierten Analysezertifikaten (COAs)
- Vollspektrum-Cannabinoide für verbesserte Wirksamkeit
- Zielgruppe umfasst Unternehmer, Kreative, Studenten und Berufstätige
Das Unternehmen befindet sich derzeit in vorläufigen Gesprächen mit Wellness-Kliniken und psychischen Gesundheitszentren über eine mögliche Integration in die Patient:innen-Routinen, obwohl noch keine formellen Vereinbarungen getroffen wurden.
- Strategic positioning in two rapidly growing markets
- High-potency product differentiation with 100MG dosage
- Lab-verified quality with available COAs
- Potential partnerships with wellness clinics and mental health centers
- No formal agreements yet with healthcare facilities
- Highly competitive CBD market space
- Premium pricing potential due to high CBD content
With the global CBD market expected to exceed
SCOTTSDALE, AZ / ACCESS Newswire / April 22, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) a leader in cannabinoid-driven health innovation - proudly announces the launch of its most anticipated product to date: a high-dosage 100MG Full Spectrum CBD Gummy, meticulously formulated to support mental health, daily focus, and emotional well-being.
Available in mouth-watering Crisp Green Apple and Wild Blueberry flavors, this isn't your average CBD gummy. It's a next-generation wellness tool - designed not only to relax the body but to sharpen the mind. Crafted with full-spectrum cannabinoids, these gummies are being positioned as a natural ally in the pursuit of mental clarity, balance, and daily productivity.
"Mental health isn't a trend - it's a global crisis. And people are tired of band-aid solutions," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "This product was built to empower people who want to feel better and function better - without the side effects of traditional pharmaceuticals. It's a powerful, natural alternative that speaks directly to the stress, anxiety, and attention struggles millions face every day."
Lab tested and verified with Certificates of Analysis (COAs), this 100MG gummy represents the company's deepest push yet into the lucrative mental wellness category. Unlike many low-dose competitors, CBDL's bold formulation is made for people who need real results - entrepreneurs, creatives, students, parents, and professionals looking to stay in control of their mood and mindset.
Early conversations with several wellness clinics and mental health centers are already in progress, exploring how this high-potency gummy could be integrated into patient routines. While no formal agreements have been made, the demand is clear: health professionals are actively seeking natural, high-quality, lab-verified CBD options to complement modern mental wellness protocols.
CBDL is rapidly building a portfolio that taps into high-value niches: from pain relief and nano-enhanced beverages to functional CBD coffee creamers and now, this cutting-edge product for mental clarity. The company's ability to stay ahead of trends and deliver results has attracted attention from both investors and the wellness industry.
"We're not trying to follow the market - we're reshaping it," Nelson added. "With this launch, we're doubling down on our belief that the future of wellness lies in functional, focused, and effective cannabinoid products."
This release is a bold statement to shareholders and the industry: CBD Life Sciences Inc. is serious about mental health. The company's momentum continues to build, and with this new launch, they're inviting wellness professionals, retail buyers, and everyday users to experience the next level of what CBD can offer.
The 100MG Mental Health Gummies are available now, with full lab reports and wholesale interest forms available on the company's website.
For product information, COAs, or wholesale inquiries, please visit www.thecbdvault.com.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. (CBDL) is a leading innovator in the wellness and alternative health sector, specializing in high-quality CBD and functional mushroom products designed to enhance well-being. With a commitment to scientific research and consumer safety, CBDL continues to push the boundaries of holistic health solutions, creating opportunities for exponential growth in a rapidly evolving market.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Stay Connected & Be the First to Try Our New Functional Mushroom Products!
Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz
Mushroom Madness Website: https://www.mushroommadness.shop
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences, Inc.
View the original press release on ACCESS Newswire
FAQ
What makes CBDL's new 100MG CBD gummy different from competitors?
How is CBDL positioning itself in the CBD and mental wellness markets?
What distribution channels is CBDL exploring for its new mental health gummies?
What is the target market for CBDL's new 100MG CBD gummies?
Where can customers verify the lab testing results for CBDL's new CBD gummies?
